Sugi Predict

Sugi Predict / Compounds / SCHEMBL14927151

SCHEMBL14927151

SCHEMBL14927151

Cc1nnc2ccc(N)nn12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 2/20 0.58
▸ ADORA3 P0DMS8 1/20 0.58
▸ ADORA2A P29274 1/20 0.58
▸ ADORA2B P29275 1/20 0.58
▸ ADORA1 P30542 1/20 0.58
▸ CREBBP Q92793 1/20 0.58
▸ SMN1; SMN2 Q16637 4/20 0.51
▸ HTT P42858 2/20 0.51
▸ KDM4E B2RXH2 6/20 0.49
▸ ALDH1A1 P00352 4/20 0.46
▸ LMNA P02545 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44
▸ MAPT P10636 2/20 0.43
▸ KMT2A Q03164 2/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ GABRA1 P14867 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ GABRG2 P18507 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14074027 0.78 KDM4E (0.64) BRD4SMN1; SMN2HTTKDM4EALDH1A1
SCHEMBL2763564 0.75 KDM4E (0.64) BRD4ADORA3ADORA2AADORA2BADORA1
SCHEMBL15834696 0.75 SMN1; SMN2 (0.51) BRD4SMN1; SMN2HTTKDM4EALDH1A1
SCHEMBL1242674 0.75 KDM4E (0.64) BRD4SMN1; SMN2HTTKDM4EALDH1A1
SCHEMBL20160225 0.75 SMN1; SMN2 (0.51) BRD4SMN1; SMN2HTTKDM4EALDH1A1
SCHEMBL10490635 0.72 KDM4E (0.63) BRD4SMN1; SMN2HTTKDM4EALDH1A1
SCHEMBL13248521 0.72 SMN1; SMN2 (0.49) BRD4SMN1; SMN2HTTKDM4EALDH1A1
SCHEMBL13248349 0.72 SMN1; SMN2 (0.49) BRD4SMN1; SMN2HTTKDM4EALDH1A1
SCHEMBL2362190 0.71 ALDH1A1 (0.64) BRD4ADORA3ADORA2AADORA2BADORA1
SCHEMBL10389396 0.70 KDM4E (0.65) BRD4SMN1; SMN2KDM4EALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4217346-B1 NEW COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2025-07-02 — — EP disclosed
US-20240043450-A1 NEW COMPOUND JANSSEN PHARMACEUTICA NV (BE) 2024-02-08 — — US disclosed
US-20230391756-A1 NEW COMPOUND JANSSEN PHARMACEUTICA NV (BE) 2023-12-07 — — US disclosed
EP-4217347-A1 NEW COMPOUNDS JANSSEN Pharmaceutica NV (BE) 2023-08-02 — — EP disclosed
EP-4217346-A1 NEW COMPOUNDS JANSSEN Pharmaceutica NV (BE) 2023-08-02 — — EP disclosed
US-20230203044-A1 PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 — — US disclosed
US-20230203044-A1 PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 — — US disclosed
US-20230203044-A1 PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 — — US disclosed
CN-116194445-A New compounds 詹森药业有限公司 2023-05-30 — — CN disclosed
EP-4135843-A1 PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY JANSSEN Pharmaceutica NV (BE) 2023-02-22 — — EP disclosed
WO-2022063896-A1 NEW COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2022-03-31 — — WO disclosed
WO-2021209552-A1 PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY JANSSEN PHARMACEUTICA NV (BE) 2021-10-21 — — WO disclosed
WO-2021209552-A1 PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY JANSSEN PHARMACEUTICA NV (BE) 2021-10-21 — — WO disclosed
US-10023556-B2 Androgen receptor modulators and uses thereof ARAGON PHARMACEUTICALS, INC. (US) 2018-07-17 — — US disclosed
US-10023556-B2 Androgen receptor modulators and uses thereof ARAGON PHARMACEUTICALS, INC. (US) 2018-07-17 — — US disclosed
US-20160376252-A1 ANDROGEN RECEPTOR MODULATORS AND USES THEREOF ARAGON PHARMACEUTICALS INC (US) 2016-12-29 — — US disclosed
US-9481664-B2 Androgen receptor modulators and uses thereof ARAGON PHARMACEUTICALS, INC. (US) 2016-11-01 — — US disclosed
US-9108944-B2 Androgen receptor modulators and uses thereof ARAGON PHARMACEUTICALS, INC. (US) 2015-08-18 — — US disclosed
US-20150182529-A1 ANDROGEN RECEPTOR MODULATORS AND USES THEREOF ARAGON PHARMACEUTICALS INC (US) 2015-07-02 — — US disclosed
US-20130116258-A1 ANDROGEN RECEPTOR MODULATORS AND USES THEREOF ARAGON PHARMACEUTICALS, INC. (US) 2013-05-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230391756-A1 NEW COMPOUND NLRP3, NLRP1, IL1R1 BRD4 939/4885ADORA3 164/4885ADORA2A 1777/4885
US-20230203044-A1 PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME NLRP3, PYCARD, NLRP1 BRD4 143/4885ADORA3 376/4885ADORA2A 430/4885
US-20130116258-A1 ANDROGEN RECEPTOR MODULATORS AND USES THEREOF AR, ESRRA, NR5A1 BRD4 1427/4885ADORA3 598/4885ADORA2A 260/4885
US-20240043450-A1 NEW COMPOUND NLRP3, NLRP1, PYCARD BRD4 340/4885ADORA3 728/4885ADORA2A 1251/4885
US-20150182529-A1 ANDROGEN RECEPTOR MODULATORS AND USES THEREOF AR, ESRRA, NR5A1 BRD4 1427/4885ADORA3 598/4885ADORA2A 260/4885
US-10023556-B2 Androgen receptor modulators and uses thereof AR, ESRRA, NR5A1 BRD4 1427/4885ADORA3 598/4885ADORA2A 260/4885
US-20160376252-A1 ANDROGEN RECEPTOR MODULATORS AND USES THEREOF AR, ESRRA, NR5A1 BRD4 1427/4885ADORA3 598/4885ADORA2A 260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.